MAPT and Alzheimer disease: In recent years, the development of ultra-sensitive immunoassays [1, 17, 20, 45] and mass spectrometry (MS) [4, 6, 13] methods have greatly expanded the knowledge regarding p-tau species in biofluids, and most importantly, highlighted their potential value as biomarkers for AD.